NCT01763866
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
See it on ClinicalTrials.gov ↗1,899 people
45.9%
54.1%
871 womenmiddle line = equal numbers1,028 men
- Phase
- PHASE3
- Paid for by
- Amgen
- Finished
- 2013-12-04
- Health conditions
- Hyperlipidemia
- Who could join
- Anyone
- Ages
- 18 Years – 80 Years
- Average age
- mean 59.8 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 94% · Black / African American 3.9% · Asian 1.3% · Other 0.4% · Native Hawaiian / Pacific Islander 0.2% · More than one race 0.1% · American Indian / Alaska Native 0.1%
Women left out
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“New York Heart association (NYHA) III or IV heart failure”
- No diabetes
Women with diabetes were turned away.
“Type 1 diabetes, poorly controlled type 2 diabetes”
Study titles and rules are shown in their original English.